This is going to be probably a progressive change in our minds. I don’t think we will have an abrupt and fast implementation of generative AI in medicine and in cancer particularly, because we need to develop the validated tools by experts that other clinicians can rely on. So there is a need, the technology is ready, we are already doing it actually, but what’s particularly important is to find the ecosystems where top key opinion leaders can actually, and medical societies like ASH or EHA can actually rely on these systems, test them, validate them and finally support their use in the broader community for education first and in the future probably as medical devices for clinical decision making...
This is going to be probably a progressive change in our minds. I don’t think we will have an abrupt and fast implementation of generative AI in medicine and in cancer particularly, because we need to develop the validated tools by experts that other clinicians can rely on. So there is a need, the technology is ready, we are already doing it actually, but what’s particularly important is to find the ecosystems where top key opinion leaders can actually, and medical societies like ASH or EHA can actually rely on these systems, test them, validate them and finally support their use in the broader community for education first and in the future probably as medical devices for clinical decision making. So our experience to be honest is very good. We are running several projects locally in Spain and I’m quite surprised to what extent my decision making has improved, particularly in areas where I’m not proficient. For example, I’m a CLL lymphoma doctor, but I do not know too much about hemostasis and thrombosis. When I’m in medical shifts during the night or during the afternoon, I get questions about these anticoagulation patients or hemophilia patients, for example. I don’t know too much about this. These pilot projects that we have done in hemophilia, in von Willebrand disease, in coagulation, have provided me insights on how to better treat my patients during medical shifts. So the generative AI is probably not going to substitute top experts. If you are a well-informed expert in lymphoma, myeloma, CLL, I mean, I think you are just the person who needs to supervise the AI and ensure that it’s doing a good job. But it’s probably going to enhance our capacity as doctors to make better decisions on those areas where we are not so smart. So the promise is big, the challenge is also important and we need to do this by combining both patient interests, doctor interests and also technology support into final products that can be validated by the community and adopted as new standards for medical education and communication.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
